Login / Signup

Safety of sugammadex for reversal of neuromuscular block.

Ghm HoningC H MartiniA BomM van VelzenM NiestersLphj AartsAlbert DahanMartijn Boon
Published in: Expert opinion on drug safety (2019)
Introduction: Sugammadex is a modified cyclodextrin that is able to reverse neuromuscular block induced by aminosteroidal neuromuscular blocking drugs. Compared to reversal with neostigmine, it reverses neuromuscular block quicker and more predictable and without cholinergic side effects. However, there have been concerns about sugammadex ability to bind other drugs and its effects on QT interval and clotting times. In addition, sugammadex might induce hypersensitivity reactions more frequently than initially anticipated. This review summarizes current evidence with regard to these and other safety aspects of sugammadex. Areas covered: This review provides an overview of the efficacy of sugammadex in various patient populations, evaluates potential interactions with other drugs and discusses adverse effects and reactions that have been reported in the literature. Expert opinion: Sugammadex quickly reverses aminosteroid neuromuscular block with less side effects compared to neostigmine. As such, it has the potential to significantly reduce the incidence of residual neuromuscular block and to improve postoperative pulmonary outcome. Current safety concerns mainly focus on hypersensitivity reactions and cardiac arrhythmias. Although the absolute risk for these events is low, ongoing vigilance and research in this area are needed.
Keyphrases
  • drug induced
  • systematic review
  • risk factors
  • left ventricular
  • pulmonary hypertension
  • heart failure
  • patients undergoing
  • ionic liquid
  • climate change
  • capillary electrophoresis